Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRI LO SPRINTEC vs JUNEL 1/20
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: June 2026 · OpiCalc Medical Review Team
Tri-Lo Sprintec is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It inhibits ovulation by suppressing gonadotropin release (FSH and LH) from the pituitary, increases viscosity of cervical mucus, and alters endometrial receptivity.
Combination estrogen-progestin contraceptive. Ethinyl estradiol is a synthetic estrogen that suppresses gonadotropin release by inhibiting hypothalamic Gn RH secretion. Norethindrone acetate is a progestin that suppresses LH surge and thickens cervical mucus to inhibit sperm penetration and alters endometrial development.
Prevention of pregnancy
Prevention of pregnancy in women who elect to use oral contraceptives,Treatment of moderate acne vulgaris for women at least 15 years old who have achieved menarche and are willing to use an oral contraceptive,Treatment of menstrual disorders (off-label),Emergency contraception (off-label)
One tablet (0.035 mg ethinyl estradiol + 0.180/0.215/0.250 mg norgestimate) orally once daily for 28-day cycle: active tablets on days 1-21, placebo on days 22-28.
One tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days, then repeat.
Ethinyl estradiol: terminal half-life approximately 17 hours. Norelgestromin (active metabolite of norgestimate): terminal half-life approximately 28 hours. Clinical context: Ethinyl estradiol half-life supports once-daily dosing with steady-state reached within 7-14 days; norelgestromin half-life allows for sustained progestogenic effect.
Ethinyl estradiol: 12-24 hours (terminal half-life). Norethindrone: 5-14 hours (terminal half-life). Achieves steady state within 5-7 days.
No specific dosing adjustment required for renal impairment. Use caution in severe renal impairment due to potential fluid retention.
No specific GFR-based dose adjustment; contraindicated in patients with renal impairment if associated with hyperkalemia or other contraindications.
Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive use. This risk increases with age and with heavy smoking (≥15 cigarettes per day) and is quite marked in women over 35 years of age. Women who use combination oral contraceptives should be strongly advised not to smoke.
FDA Category X. Use contraindicated in pregnancy due to risk of congenital anomalies, particularly cardiovascular and limb defects, from exposure during first trimester. Second and third trimester exposure associated with potential for fetal harm, including androgenization of female fetuses and liver adenoma. Discontinue promptly if pregnancy occurs.
FDA Pregnancy Category X. Contraindicated in pregnancy. First trimester: Use associated with congenital anomalies, including cardiovascular defects and neural tube defects. Second and third trimesters: May cause fetal harm, including feminization of male fetuses and other adverse outcomes. Discontinue immediately if pregnancy occurs.
Tri-Lo Sprintec is a triphasic oral contraceptive with ethinyl estradiol and norgestimate. Monitor for thromboembolic events, especially in smokers over 35. Advise use of backup contraception if vomiting/diarrhea occurs. CYP3A4 inducers may reduce efficacy.
Junel 1/20 is a low-dose combined oral contraceptive (COC) containing ethinyl estradiol 20 mcg and norethindrone acetate 1 mg. It is indicated for contraception but not for emergency contraception. Monitor for breakthrough bleeding, especially in first 3 months. CYP3A4 inducers (e.g., rifampin, St. John's wort) may reduce efficacy. Risk of venous thromboembolism (VTE) is lower than with 30-35 mcg EE pills but still present; counsel about smoking cessation if >35 years old.
No interactions on record
No interactions on record
Common clinical questions about TRI LO SPRINTEC vs JUNEL 1/20, answered by our medical review team.
TRI LO SPRINTEC is a Oral Contraceptive that works by Tri-Lo Sprintec is a combination oral contraceptive containing ethinyl estradiol and norgestimate. It inhibits ovulation by suppressing gonadotropin release (FSH and LH) from the pituitary, increases viscosity of cervical mucus, and alters endometrial receptivity.. JUNEL 1/20 is a Oral Contraceptive that works by Combination estrogen-progestin contraceptive. Ethinyl estradiol is a synthetic estrogen that suppresses gonadotropin release by inhibiting hypothalamic Gn RH secretion. Norethindrone acetate is a progestin that suppresses LH surge and thickens cervical mucus to inhibit sperm penetration and alters endometrial development.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRI LO SPRINTEC and JUNEL 1/20 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRI LO SPRINTEC is: One tablet (0.035 mg ethinyl estradiol + 0.180/0.215/0.250 mg norgestimate) orally once daily for 28-day cycle: active tablets on days 1-21, placebo on days 22-28.. The standard adult dose of JUNEL 1/20 is: One tablet (1 mg norethindrone acetate/20 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days, then repeat.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRI LO SPRINTEC and JUNEL 1/20 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRI LO SPRINTEC is classified as Category C. FDA Category X. Use contraindicated in pregnancy due to risk of congenital anomalies, particularly cardiovascular and limb defects, from exposure during first trimester. Second and. JUNEL 1/20 is classified as Category C. FDA Pregnancy Category X. Contraindicated in pregnancy. First trimester: Use associated with congenital anomalies, including cardiovascular defects and neural tube defects. Second . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.
Ethinyl estradiol is metabolized primarily via CYP3A4; norgestimate is rapidly metabolized to norelgestromin and subsequently to norgestrel, with further metabolism involving CYP3A4 and other CYP enzymes.
Ethinyl estradiol is primarily metabolized by CYP3A4, with additional contributions from CYP2C9 and CYP2C19. Norethindrone acetate is metabolized via reduction and conjugation (glucuronidation and sulfation). Both undergo first-pass metabolism in the liver and intestinal wall.
Renal (approximately 50-60% as metabolites, with about 20% as unchanged ethinyl estradiol glucuronide and 40% as norgestimate metabolites). Fecal (approximately 30-40% as metabolites).
Renal: 30-50% (metabolites as glucuronide and sulfate conjugates). Fecal: 20-40% (biliary elimination of metabolites). Unchanged drug: <5% renal.
Ethinyl estradiol: approximately 97-98% bound to albumin, 2% free. Norelgestromin: approximately 99% bound to sex hormone-binding globulin (SHBG) and albumin.
Ethinyl estradiol: 97-98% bound to albumin and SHBG. Norethindrone: 90% bound to albumin and SHBG.
Ethinyl estradiol: Vd approximately 4-5 L/kg. Norelgestromin: Vd approximately 3-4 L/kg. Clinical meaning: indicates extensive distribution into tissues, not primarily confined to plasma volume.
Ethinyl estradiol: 2.5-4.0 L/kg. Norethindrone: 2.5-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: ethinyl estradiol bioavailability approximately 45% (first-pass effect); norgestimate prodrug converted to norelgestromin with systemic bioavailability of approximately 63%.
Oral: Ethinyl estradiol 38-48% (first-pass metabolism). Norethindrone 50-65% (first-pass metabolism).
Contraindicated in severe hepatic disease or hepatocellular carcinoma. For mild to moderate hepatic impairment (Child-Pugh A or B), use alternative contraception; no established dosing guidelines.
Contraindicated in Child-Pugh class B or C (moderate to severe hepatic impairment). For mild impairment (Child-Pugh A), use with caution; no specific dose adjustment established.
Not indicated for use before menarche. Post-menarche: same dosing as adults (one tablet daily). Safety and efficacy established in females of reproductive age.
Post-menarche adolescents: same dosing as adults (1 tablet daily for 21 days, then 7 placebo days). Weight-based dosing not applicable.
Not indicated for postmenopausal women; no geriatric dosing established.
Not indicated for postmenopausal women; use only in reproductive-age individuals.
Cigarette smoking increases the risk of serious cardiovascular events from oral contraceptive use. This risk increases with age (especially in women over 35 years) and with the number of cigarettes smoked. Women who use oral contraceptives should be strongly advised not to smoke.
No significant food interactions. Grapefruit may slightly alter estrogen metabolism but clinically not significant. Maintain consistent dietary habits if constipating.
No known significant food interactions. Grapefruit juice may slightly increase estrogen levels but not clinically relevant. Avoid St. John's wort (herbal supplement) as it induces CYP3A4 and reduces contraceptive efficacy.
Enters breast milk in small amounts (M/P ratio not established). May reduce milk production and quality. Use caution in nursing mothers, especially during early postpartum period. Consider alternative contraception until weaning.
Small amounts of ethinyl estradiol and norethindrone are excreted in human milk. No significant adverse effects reported in nursing infants. M/P ratio not established. May reduce milk production. Use with caution in breastfeeding women, especially during early postpartum period.
Contraindicated in pregnancy; no dose adjustments recommended as use is precluded. If inadvertently used, discontinue immediately.
Not applicable; drug is contraindicated in pregnancy. No dose adjustments recommended as it should not be used.
Take one tablet daily at the same time; missed doses increase pregnancy risk.,Use backup contraception for 7 days after missing 2 or more pills.,Report symptoms of blood clots: leg pain/swelling, chest pain, sudden shortness of breath.,Avoid smoking while on this medication, especially if over 35.,May cause irregular bleeding initially; contact provider if persistent.
Take one tablet daily at the same time; if a pill is missed, follow package instructions.,Use backup contraception (e.g., condoms) for the first 7 days of starting or after a missed pill.,Do not smoke while on this medication, especially if over 35, as it increases the risk of blood clots.,Report signs of blood clots (leg pain/swelling, sudden chest pain, difficulty breathing) or liver problems (yellow skin/eyes, dark urine).,Antibiotics (except rifampin) do not reduce contraceptive efficacy; verify with pharmacist.,Mild side effects (nausea, headache, breast tenderness) often improve after 2-3 cycles.